Drugs /

serplulimab

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.

Clinical Trials

View Clinical Trials for serplulimab

Serplulimab has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating serplulimab, 1 is phase 2 (1 open) and 4 are phase 3 (4 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for serplulimab clinical trials.

Adenosquamous lung carcinoma, colorectal adenocarcinoma, and gastric carcinoma are the most common diseases being investigated in serplulimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Serplulimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating serplulimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hlx-10, serplulimab, hlx10, hlx 10
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C156738

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.